Saruparib (AZD5305) Clinical Trials
4 recruitingDrug
Phase 13Phase 31Phase 21
Showing 1–4 of 4 trials
Recruiting
Phase 3
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Advanced Breast Cancer
AstraZeneca500 enrolled298 locationsNCT06380751
Recruiting
Phase 1
AZD5305 hADME in Patients With Advanced Solid Malignancies
Locally Advanced or Metastatic Solid Tumor
AstraZeneca8 enrolled2 locationsNCT06713369
Recruiting
Phase 1Phase 2
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Ovarian CancerEndometrial CancerLung Adenocarcinoma
AstraZeneca506 enrolled60 locationsNCT05797168
Recruiting
Phase 1
A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.
Prostate Cancer
AstraZeneca120 enrolled19 locationsNCT05938270